3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Breast Neoplasms
12
Ovarian Neoplasms
11
Fallopian Tube Neoplasms
10
Carcinoma, Non-Small-Cell Lung
7
Pancreatic Neoplasms
5
Brenner Tumor
5
Lung Neoplasms
4
Endometrial Neoplasms
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Carcinoma
3
Adenocarcinoma of Lung
3
Oropharyngeal Neoplasms
2
Neurotoxicity Syndromes
2
Mouth Neoplasms
2
Laryngeal Neoplasms
2
Hypopharyngeal Neoplasms
2
Carcinosarcoma
2
Carcinoma, Transitional Cell
2
Vomiting
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrent Uterine Corpus Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Cancer Resectable
1
Pancreatic Adenocarcinoma
1
Pancreas Adenocarcinoma
1
Pain
1
Ovarian Germ Cell Cancer
1
Interventions
Epoetin Alfa
27
Darbepoetin alfa
13
epoetin beta
3
Erythropoietin
3
telapristone acetate
2
luspatercept
2
ferric carboxymaltose
2
Lenalidomide
2
Ferric Oxide, Saccharated
2
Cisplatin
2
Blood Transfusion
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
ibrutinib
1
fludarabine phosphate
1
fludarabine
1
ferrous sulfate
1
ferric gluconate
1
ferric derisomaltose
1
fanasil, pyrimethamine drug combination
1
Taxes
1
Sugars
1
Sucrose
1
Solutions
1
Saline Solution
1
Rituximab
1
Radiotherapy
1
Pharmacogenomic Testing
1
Paclitaxel
1
Iron-Dextran Complex
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Anemia
×
Taxes
×
Clear all
NCT06018883
2025-08-07
PTCA199-3
Fudan University
Phase 3
Active not recruiting
100 enrolled